Real-time Estimate
Cboe BZX
07:45:37 03/06/2024 pm IST
|
5-day change
|
1st Jan Change
|
4.835
USD
|
+3.31%
|
|
-1.85%
|
-59.34%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,473
|
4,950
|
7,444
|
2,696
|
3,765
|
1,534
|
-
|
-
|
Enterprise Value (EV)
1 |
3,614
|
4,949
|
7,099
|
2,485
|
3,765
|
1,803
|
1,769
|
1,605
|
P/E ratio
|
92.2
x
|
757
x
|
32.7
x
|
-15.4
x
|
-45.3
x
|
-58.3
x
|
32.3
x
|
25.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.78
x
|
9.88
x
|
12
x
|
3.59
x
|
4.82
x
|
1.74
x
|
1.48
x
|
1.32
x
|
EV / Revenue
|
8.1
x
|
9.88
x
|
11.5
x
|
3.31
x
|
4.82
x
|
2.05
x
|
1.71
x
|
1.38
x
|
EV / EBITDA
|
29.3
x
|
46.4
x
|
66.2
x
|
24.4
x
|
56.7
x
|
18.5
x
|
9.31
x
|
6.65
x
|
EV / FCF
|
332
x
|
-91.1
x
|
2,155
x
|
114
x
|
-
|
-8.8
x
|
26.4
x
|
15
x
|
FCF Yield
|
0.3%
|
-1.1%
|
0.05%
|
0.88%
|
-
|
-11.4%
|
3.79%
|
6.66%
|
Price to Book
|
7.25
x
|
6.86
x
|
5.44
x
|
2.27
x
|
-
|
1.43
x
|
1.36
x
|
1.33
x
|
Nbr of stocks (in thousands)
|
1,50,653
|
1,63,476
|
1,75,162
|
1,76,703
|
1,76,936
|
1,77,292
|
-
|
-
|
Reference price
2 |
23.05
|
30.28
|
42.50
|
15.26
|
21.28
|
8.655
|
8.655
|
8.655
|
Announcement Date
|
26/03/20
|
25/03/21
|
12/04/22
|
12/05/23
|
24/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
446.4
|
500.9
|
618
|
751.4
|
781.4
|
881.4
|
1,037
|
1,160
|
EBITDA
1 |
123.1
|
106.6
|
107.3
|
101.7
|
66.35
|
97.26
|
190.1
|
241.3
|
EBIT
1 |
62.59
|
48.52
|
41
|
20.85
|
-26.63
|
-9.858
|
68.17
|
110.9
|
Operating Margin
|
14.02%
|
9.69%
|
6.63%
|
2.77%
|
-3.41%
|
-1.12%
|
6.58%
|
9.57%
|
Earnings before Tax (EBT)
1 |
56.56
|
25.81
|
237
|
-154
|
-80.59
|
-32.18
|
39.42
|
98.73
|
Net income
1 |
38.07
|
6.252
|
215.5
|
-175.7
|
-83.91
|
-27.89
|
32.32
|
76.84
|
Net margin
|
8.53%
|
1.25%
|
34.87%
|
-23.38%
|
-10.74%
|
-3.16%
|
3.12%
|
6.63%
|
EPS
2 |
0.2500
|
0.0400
|
1.300
|
-0.9900
|
-0.4700
|
-0.1484
|
0.2683
|
0.3372
|
Free Cash Flow
1 |
10.89
|
-54.35
|
3.294
|
21.75
|
-
|
-205
|
67
|
107
|
FCF margin
|
2.44%
|
-10.85%
|
0.53%
|
2.89%
|
-
|
-23.26%
|
6.46%
|
9.23%
|
FCF Conversion (EBITDA)
|
8.85%
|
-
|
3.07%
|
21.4%
|
-
|
-
|
35.24%
|
44.34%
|
FCF Conversion (Net income)
|
28.61%
|
-
|
1.53%
|
-
|
-
|
-
|
207.33%
|
139.26%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/03/20
|
25/03/21
|
12/04/22
|
12/05/23
|
24/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
231
|
187.1
|
164.7
|
172.2
|
336.9
|
173.9
|
240.7
|
170.3
|
383.8
|
196.3
|
250.1
|
208.7
|
207.6
|
229.9
|
250.7
|
245.5
|
245.8
|
EBITDA
1 |
47.27
|
37.21
|
18.9
|
14.7
|
33.64
|
10.96
|
57.05
|
-
|
26.1
|
24.11
|
16.14
|
7.815
|
19.73
|
27.37
|
36.09
|
-
|
-
|
EBIT
1 |
18.92
|
14.94
|
0.463
|
-3.77
|
-3.307
|
-13.53
|
37.69
|
-36.29
|
-
|
-12.19
|
-7.687
|
-14.74
|
-4.233
|
2.116
|
10.18
|
-
|
-
|
Operating Margin
|
8.19%
|
7.99%
|
0.28%
|
-2.19%
|
-0.98%
|
-7.78%
|
15.66%
|
-21.31%
|
-
|
-6.21%
|
-3.07%
|
-7.06%
|
-2.04%
|
0.92%
|
4.06%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-17.84
|
-
|
-24.34
|
-
|
-43.36
|
-17.52
|
-20.44
|
-
|
-29.92
|
-24.02
|
-26.78
|
-2.761
|
5.756
|
13.64
|
-
|
-
|
Net income
1 |
-
|
-31.48
|
-73.24
|
-27.94
|
-101.2
|
-47.28
|
-27.2
|
-14.93
|
-28.83
|
-38.96
|
-16.13
|
-20.67
|
-11.7
|
-1.051
|
2.121
|
-
|
-
|
Net margin
|
-
|
-16.83%
|
-44.48%
|
-16.22%
|
-30.03%
|
-27.19%
|
-11.3%
|
-8.77%
|
-7.51%
|
-19.85%
|
-6.45%
|
-9.9%
|
-5.63%
|
-0.46%
|
0.85%
|
-
|
-
|
EPS
2 |
-
|
-0.2000
|
-0.4100
|
-0.1600
|
-0.5700
|
-0.2700
|
-0.1500
|
-0.0800
|
-
|
-0.2200
|
-0.0900
|
-0.1200
|
-0.0400
|
-0.0200
|
0.0200
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/08/20
|
12/04/22
|
11/05/22
|
11/08/22
|
11/08/22
|
09/11/22
|
12/05/23
|
29/08/23
|
29/08/23
|
08/11/23
|
24/04/24
|
22/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
141
|
-
|
-
|
-
|
-
|
269
|
235
|
71
|
Net Cash position
1 |
-
|
0.67
|
345
|
212
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.149
x
|
-
|
-
|
-
|
-
|
2.766
x
|
1.236
x
|
0.2942
x
|
Free Cash Flow
1 |
10.9
|
-54.4
|
3.29
|
21.8
|
-
|
-205
|
67
|
107
|
ROE (net income / shareholders' equity)
|
8.45%
|
1.04%
|
20.5%
|
-13.7%
|
-
|
-5.64%
|
4.94%
|
5.47%
|
ROA (Net income/ Total Assets)
|
3.89%
|
0.47%
|
11.7%
|
-7.82%
|
-
|
0.8%
|
1.13%
|
2.06%
|
Assets
1 |
978.7
|
1,322
|
1,849
|
2,246
|
-
|
-3,486
|
2,860
|
3,735
|
Book Value Per Share
2 |
3.180
|
4.420
|
7.810
|
6.720
|
-
|
6.030
|
6.360
|
6.490
|
Cash Flow per Share
2 |
0.2800
|
0.2900
|
0.7300
|
1.150
|
-
|
0.1900
|
0.7600
|
0.9400
|
Capex
1 |
31.3
|
99.1
|
119
|
181
|
-
|
160
|
116
|
127
|
Capex / Sales
|
7.02%
|
19.78%
|
19.25%
|
24.13%
|
-
|
18.18%
|
11.2%
|
10.92%
|
Announcement Date
|
26/03/20
|
25/03/21
|
12/04/22
|
12/05/23
|
24/04/24
|
-
|
-
|
-
|
Last Close Price
8.655
EUR Average target price
20.79
EUR Spread / Average Target +140.21% Consensus |
1st Jan change
|
Capi.
|
---|
| +51.13% | 5.46TCr | | -4.95% | 3.99TCr | | +37.60% | 3.88TCr | | +15.49% | 2.69TCr | | -12.56% | 2.62TCr | | -21.61% | 1.88TCr | | +25.32% | 1.22TCr | | +1.97% | 1.22TCr | | +26.93% | 1.19TCr |
Other Biotechnology & Medical Research
|